Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
89% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. INSY: No Debt )
INSY' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.77
INSY's Equity to Asset is ranked higher than
80% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INSY: 0.77 )
INSY' s 10-Year Equity to Asset Range
Min: -4.6   Max: 1
Current: 0.77

-4.6
1
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
95% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
INSY' s 10-Year Interest Coverage Range
Min: 34.27   Max: 9999.99
Current: No Debt

34.27
9999.99
F-Score: 6
Z-Score: 28.42
M-Score: -1.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 28.82
INSY's Operating margin (%) is ranked higher than
96% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. INSY: 28.82 )
INSY' s 10-Year Operating margin (%) Range
Min: -324863.64   Max: 56.36
Current: 28.82

-324863.64
56.36
Net-margin (%) 17.10
INSY's Net-margin (%) is ranked higher than
93% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. INSY: 17.10 )
INSY' s 10-Year Net-margin (%) Range
Min: -301890.91   Max: 40.67
Current: 17.1

-301890.91
40.67
ROE (%) 31.18
INSY's ROE (%) is ranked higher than
97% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. INSY: 31.18 )
INSY' s 10-Year ROE (%) Range
Min: -223.53   Max: 545.67
Current: 31.18

-223.53
545.67
ROA (%) 24.47
INSY's ROA (%) is ranked higher than
98% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. INSY: 24.47 )
INSY' s 10-Year ROA (%) Range
Min: -118.94   Max: 67.69
Current: 24.47

-118.94
67.69
ROC (Joel Greenblatt) (%) 165.33
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. INSY: 165.33 )
INSY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2087.93   Max: 775
Current: 165.33

-2087.93
775
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

INSY Guru Trades in Q1 2014

Steven Cohen 9,088 sh (New)
Jim Simons 137,080 sh (New)
Joel Greenblatt 16,982 sh (-29.72%)
» More
Q2 2014

INSY Guru Trades in Q2 2014

Paul Tudor Jones 17,626 sh (New)
Joel Greenblatt 30,111 sh (+77.31%)
Steven Cohen 168,700 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

INSY Guru Trades in Q3 2014

Chase Coleman 300,000 sh (New)
Steven Cohen 675,765 sh (+300.57%)
Paul Tudor Jones 22,394 sh (+27.05%)
Joel Greenblatt Sold Out
» More
Q4 2014

INSY Guru Trades in Q4 2014

Chase Coleman Sold Out
Steven Cohen 603,750 sh (-10.66%)
Paul Tudor Jones 12,448 sh (-44.41%)
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 58.30
INSY's P/E(ttm) is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 58.30 )
INSY' s 10-Year P/E(ttm) Range
Min: 17.67   Max: 2102.36
Current: 58.3

17.67
2102.36
Forward P/E 18.76
INSY's Forward P/E is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 18.76 )
N/A
PE(NRI) 59.00
INSY's PE(NRI) is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 59.00 )
INSY' s 10-Year PE(NRI) Range
Min: 17.69   Max: 2943.3
Current: 59

17.69
2943.3
P/B 13.10
INSY's P/B is ranked lower than
53% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. INSY: 13.10 )
INSY' s 10-Year P/B Range
Min: 0.05   Max: 19.89
Current: 13.1

0.05
19.89
P/S 10.00
INSY's P/S is ranked higher than
73% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. INSY: 10.00 )
INSY' s 10-Year P/S Range
Min: 1.74   Max: 30459.5
Current: 10

1.74
30459.5
PFCF 80.60
INSY's PFCF is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 80.60 )
INSY' s 10-Year PFCF Range
Min: 29.42   Max: 173.14
Current: 80.6

29.42
173.14
POCF 45.02
INSY's POCF is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 45.02 )
INSY' s 10-Year POCF Range
Min: 21.62   Max: 2061.3
Current: 45.02

21.62
2061.3
EV-to-EBIT 31.53
INSY's EV-to-EBIT is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 31.53 )
INSY' s 10-Year EV-to-EBIT Range
Min: -83.2   Max: 103.5
Current: 31.53

-83.2
103.5
Current Ratio 3.31
INSY's Current Ratio is ranked higher than
67% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. INSY: 3.31 )
INSY' s 10-Year Current Ratio Range
Min: 0.14   Max: 318.82
Current: 3.31

0.14
318.82
Quick Ratio 2.55
INSY's Quick Ratio is ranked higher than
64% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. INSY: 2.55 )
INSY' s 10-Year Quick Ratio Range
Min: 0.06   Max: 318.82
Current: 2.55

0.06
318.82
Days Inventory 403.71
INSY's Days Inventory is ranked higher than
77% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 403.71 )
INSY' s 10-Year Days Inventory Range
Min: 169.77   Max: 1095
Current: 403.71

169.77
1095
Days Sales Outstanding 43.62
INSY's Days Sales Outstanding is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. INSY: 43.62 )
INSY' s 10-Year Days Sales Outstanding Range
Min: 0.37   Max: 72.85
Current: 43.62

0.37
72.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 63.60
INSY's Price/Net Cash is ranked higher than
56% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. INSY: 63.60 )
INSY' s 10-Year Price/Net Cash Range
Min: 1   Max: 44.38
Current: 63.6

1
44.38
Price/Net Current Asset Value 30.20
INSY's Price/Net Current Asset Value is ranked higher than
58% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. INSY: 30.20 )
INSY' s 10-Year Price/Net Current Asset Value Range
Min: 0.98   Max: 96.48
Current: 30.2

0.98
96.48
Price/Tangible Book 12.90
INSY's Price/Tangible Book is ranked higher than
52% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. INSY: 12.90 )
INSY' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 105.92
Current: 12.9

0.62
105.92
Price/DCF (Projected) 23.40
INSY's Price/DCF (Projected) is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 23.40 )
INSY' s 10-Year Price/DCF (Projected) Range
Min: 5.54   Max: 16.34
Current: 23.4

5.54
16.34
Price/Graham Number 5.70
INSY's Price/Graham Number is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INSY: 5.70 )
INSY' s 10-Year Price/Graham Number Range
Min: 3.19   Max: 5.31
Current: 5.7

3.19
5.31
Earnings Yield (Greenblatt) 3.30
INSY's Earnings Yield (Greenblatt) is ranked higher than
92% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. INSY: 3.30 )
INSY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 3669.5
Current: 3.3

1
3669.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPR1.Germany,
Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subsys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.
» More Articles for INSY

Headlines

Articles On GuruFocus.com
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel fo Jan 26 2015 
Insys Therapeutics to Initiate Five Phase III Clinical Trials in 2015 Jan 12 2015 
Insys Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference Jan 05 2015 
Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a Poten Dec 09 2014 
Parallel Comparison Analyses Confirm That Insys Therapeutics' Synthetic CBD Is Identical in Chemical Dec 04 2014 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Pote Nov 24 2014 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Pote Oct 15 2014 

More From Other Websites
Making Money With Charles Payne: 04/17/15 Apr 17 2015
Lightning Round: Be careful-this lurks everywhere Apr 01 2015
Cramer Remix: It's time to buy these oil stocks Apr 01 2015
INSYS THERAPEUTICS, INC. Financials Mar 11 2015
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Mar 03 2015
Insys Therapeutics Q4 Beat Drives Short-Lived Rally Mar 03 2015
INSYS Therapeutics Slumps: INSY Falls 7% in Session - Tale of the Tape Mar 03 2015
Insys Therapeutics tops 4Q revenue forecasts Mar 03 2015
Insys Therapeutics tops 4Q revenue forecasts Mar 03 2015
Insys Therapeutics Announces Its Pharmaceutical Cannabidiol Received Fast Track Designation From FDA... Mar 03 2015
Insys Therapeutics Reports Fourth Quarter and Year End 2014 Results Mar 03 2015
Q4 2014 Insys Therapeutics Inc Earnings Release - Before Market Open Mar 03 2015
Insys Therapeutics Reports Fourth Quarter and Year End 2014 Results Mar 03 2015
The Shuman Law Firm Investigates INSYS Therapeutics, Inc. Mar 02 2015
Medivation Tops Q4 Views On Strong Xtandi Results Feb 26 2015
Insys Therapeutics Announces Its Pharmaceutical Cannabidiol Received Fast Track Designation From FDA... Feb 26 2015
The hot health care stocks to buy now for your 401(K) Feb 25 2015
United Therapeutics Blood Pressure Drug Lifts Q4 Feb 24 2015
Insys Therapeutics In-Licenses Novel Mast Cell Therapy for Chronic Pelvic Pain Feb 24 2015
Insys Therapeutics In-Licenses Novel Mast Cell Therapy for Chronic Pelvic Pain Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK